The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BPTH Detailed Price Forecast - CNN Money||View BPTH Detailed Summary - Google Finance|
|View BPTH Detailed Summary - Yahoo! Finance||View BPTH Stock Research & Analysis - Zacks.com|
|View BPTH Trends & Analysis - Trade-Ideas||View BPTH Major Holders - Barrons|
|View BPTH Call Transcripts - NASDAQ||View BPTH Breaking News & Analysis - Seeking Alpha|
|View BPTH Annual Report - CompanySpotlight.com||View BPTH OTC Short Report - OTCShortReport.com|
|View BPTH Fundamentals - TradeKing||View BPTH SEC Filings - Bar Chart|
|View Historical Prices for BPTH - The WSJ||View Performance/Total Return for BPTH - Morningstar|
|View the Analyst Estimates for BPTH - MarketWatch||View the Earnings History for BPTH - CNBC|
|View the BPTH Earnings - StockMarketWatch||View BPTH Buy or Sell Recommendations - MacroAxis|
|View the BPTH Bullish Patterns - American Bulls||View BPTH Short Pain Metrics - ShortPainBot.com|
|View BPTH Stock Mentions - StockTwits||View BPTH Stock Mentions - PennyStockTweets|
|View BPTH Stock Mentions - Twitter||View BPTH Investment Forum News - Investor Hub|
|View BPTH Stock Mentions - Yahoo! Message Board||View BPTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for BPTH - SECform4.com||View Insider Transactions for BPTH - Insider Cow|
|View BPTH Major Holdings Summary - CNBC||View Insider Disclosure for BPTH - OTC Markets|
|View Insider Transactions for BPTH - Yahoo! Finance||View Institutional Holdings for BPTH - NASDAQ|
|View BPTH Stock Insight & Charts - FinViz.com||View BPTH Investment Charts - StockCharts.com|
|View BPTH Stock Overview & Charts - BarChart||View BPTH User Generated Charts - Trading View|
Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering
Posted on Friday September 21, 2018
Bio-Path will issue to the investors warrants to purchase up to 2,261,538 shares of common stock, which represents 100% of the number of shares of common stock issued in the registered direct offering, with an exercise price $0.96 per share and exercise period commencing six (6) months following the issuance date and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.
Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Posted on Wednesday August 29, 2018
HOUSTON, Aug. 29, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia
Posted on Monday August 27, 2018
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it has commenced Stage 2 of the company’s Phase 2 trial of prexigebersen in acute myeloid leukemia. “We are delighted to announce the expansion of our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia using a dosing schedule that administers a greater amount of prexigebersen to the patient prior to commencing LDAC dosing than in the first part of the trial.
Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board
Posted on Thursday August 16, 2018
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Jason B. Fleming, M.D., F.A.C.S., to its Scientific Advisory Board (SAB). “We are thrilled to welcome Dr. Fleming to our scientific advisory board. As a leader in the treatment of gastrointestinal cancers, Dr. Fleming will be able to offer substantial insight as we seek to advance our lead drug candidate prexigebersen and our third drug candidate, BP1003, towards the clinic for the treatment of pancreatic cancer,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.